Since the worldwide discovery of individuals harboring natural mutations of PCSK9, clinical studies have established a causative association between “gain of function” (GOF) mutations with hypercholesterolemia [4] and “loss of function” (LOF) mutations with hypocholesterolemia [14]. Here, PCSK9 is linked to familial hypercholesterolemia.